Heart pill approval a much-needed win for AZ

Share this article:

AstraZeneca said it won approval today for Epanova, a treatment for patients with severe hypertriglyceridemia.

It's the first prescription omega-3 with a two-capsule, once-a-day dosing option, AZ said, something that could give it an edge among fish oil-based cardiovascular pills like GSK's Lovaza and Amarin's Vascepa, as patients with severely high trigs often have other conditions such as diabetes and high blood pressure that require them to take multiple meds.

AZ acquired the omega-3 drug when it bought Omthera Pharmaceuticals last year for up to $443 million. According to Thomson Reuters Pharma, which polled industry analysts, the drug could reach sales of $322 million by 2018.

It came as a small but symbolic win as the British firm fends off a $106-billion takeover attempt from Pfizer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.